NEW YORK , Oct. 23, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Exelixis, Inc. ("Exelixis" or the "Company") (NASDAQ: EXEL). Such investors are advised to c
Sequoia Financial Advisors LLC purchased a new stake in Exelixis, Inc. (NASDAQ: EXEL) in the undefined quarter, according to its most recent filing with the SEC. The institutional investor purchased 6
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) announced today that its third quarter 2025 financial results will be released on Tuesday, November 4, 2025 after the markets close. At
Exelixis Inc. (NASDAQ:EXEL) stock is trading lower on Monday after the company shared detailed results from the STELLAR-303 Phase 3 trial.
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced detailed results from STELLAR-303, a global phase 3 pivotal trial evaluating zanzalintinib in combination with atezolizu
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced results from a subgroup analysis of the CABINET phase 3 pivotal trial evaluating CABOMETYX® (cabozantinib) versus place
Finding great biotech stocks to invest in at a price point of $50 per share (or less) isn't easy. There are plenty of companies in the industry trading for far less money than that, but they tend to b
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Every investor wants to outperform the market, but it's a challenging feat to achieve. That's why few manage to do it consistently over long periods.
Exelixis, Inc. (NASDAQ:EXEL ) Bernstein 2nd Annual Global Healthcare Conference September 24, 2025 8:50 AM EDT Company Participants Michael Morrissey - CEO, President & Director Conference Call Partic
NEW YORK , Sept. 13, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Exelixis, Inc. ("Exelixis" or the "Company") (NASDAQ: EXEL).
NEW YORK, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Exelixis, Inc. (“Exelixis” or the “Company”) (NASDAQ: EXEL).  Such investors
Exelixis, Inc. (NASDAQ:EXEL ) H.C. Wainwright 27th Annual Global Investment Conference September 10, 2025 8:00 AM EDT Company Participants Christopher Senner - Executive VP & CFO Andrew Peters - Senio
Exelixis, Inc. (NASDAQ:EXEL ) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 8:30 AM EDT Company Participants Michael Morrissey - CEO, President & Director Conference Call P
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE